Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.

Abstract

We determined the effectiveness and toxicity of combined chemotherapy consisting of etoposide 100 mg/m(2)/day i.v. and cladribine (2-CdA) 0.12 mg/kg/day i.v. each for 5 days (EC regimen) in the treatment of refractory or relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The cycles were repeated every 28 days, reaching a maximum of six courses. Twenty patients entered the study. All patients had received three or more cycles of chemotherapy before the EC regimen (median 8, range 3-19). Thirteen patients received 2-CdA before the EC regimen. Seven out of 20 patients (35%) responded, including one complete response. Median overall survival time of responding patients was 22 months (range 3-30). Myelosuppression and infections were the major toxicity of the EC regimen.

• Authors: T Robak, A Szmigielska-Kapłon, J Z Błoński, M Kasznicki, K Chojnowski
• Journal: Chemotherapy (Chemotherapy) Vol. 51 Issue 5 Pg. 247-51 (Aug 2005) ISSN: 0009-3157 [Print] Switzerland
• PMID: 16088121 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2005 S. Karger AG, Basel.

Chemical References

• Cladribine
• Etoposide

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Cladribine (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Humans
• Infections (chemically induced)
• Infusions, Intravenous
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Middle Aged
• Neutropenia (chemically induced)
• Recurrence
• Survival Analysis
• Treatment Outcome